How Value Analysis Committees’ Lines of Questioning Can Directly Affect Value Equation Outputs

By AHRMM

John Kelty from W.L. Gore & Associates discusses how value analysis committees can determine a medical devices value when evaluating new products. 

Related Resources

Advisory
Statement on Pricing Transparency
AHRMM’s Issues & Legislative Committee issued the following Statement on Pricing Transparency approved by AHRMM Board of Directors:<
Advisory
UDI and Adverse Event Reporting Advisory
The Food and Drug Administration (FDA) UDI system is being phased in over several years.
On-Demand Educational Webinars
Service Contracts: Impacting the Total Cost of Ownership
AHRMM Cost, Quality and Outcomes (CQO) Movement
The AHRMM Cost, Quality, and Outcomes (CQO) Movement frames the critical role supply chain professionals play in driving high quality care, at a more…